U.S. Lifts 100% Tariff on Specialty Drugs from India and 19 Partner Countries

Washington announced a significant shift in its trade policy affecting the pharmaceutical sector. Effective immediately, the United States will exempt specialty medicines and related components that originate in India and 19 other partner jurisdictions from the 100% tariff that had previously been applied.

The move, detailed in a release on September 29, is being framed as a boost to international trade and an effort to improve the flow of high‑cost, life‑saving drugs into the U.S. market. While the exact list of eligible products was not disclosed, the exemption covers “select speciality medications and related components,” suggesting a focus on complex therapies such as biologics, oncology agents, and rare‑disease treatments.

For the South‑Asian diaspora, the decision could have multiple implications. Indian pharmaceutical firms that already supply a large share of generic and biosimilar drugs to the U.S. may see reduced export costs and wider market access. Moreover, the policy could indirectly lower prices for patients, including the growing Indian‑American community, who rely on these treatments. Industry observers note that the exemption signals a broader U.S. willingness to engage with established drug‑exporting partners amid global supply‑chain challenges.

The exemption is part of a broader negotiation framework with partner countries, and officials indicated that similar arrangements may be explored in the future.